Clinical trials: Watch & Wait
Rectal Cancer
Response-adapted Total Neoadjuvant Therapy Guided by Induction Chemotherapy in Early- and Intermediate-risk Low Rectal Cancer for Implementation of a Watch-and-wait Strategy
This study investigates the feasibility of an organ-preserving "watch-and-wait" strategy in patients with mid-to-low rectal cancer who achieve a good response after total neoadjuvant therapy (TNT).
- Trial name
- NCT07260526
- Where
- China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Muscle-invasive Bladder Cancer
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
The purpose of this study is to assess the efficacy and safety of adding the immunotherapy Avelumab as a fourth component, alongside tumor removal, chemotherapy, and radiation, to increase the chance of preserving the bladder in…
- Trial name
- NCT06686381
- Testing
- Maximum TURBT, Chemotherapy + Immunotherapy Induction, Radiotherapy
- Where
- Lebanon
- Volunteers
- 80 people
- Sponsor
- American University of Beirut Medical Center
Rectal Cancer, Organ Preservation
Treatment Strategy for Rectal Cancer Patients With Complete Clinical Response
This was a propensity-score matched observational analysis, comparing the oncological outcome of surgical resection vs watch and wait apporach for rectal cancer patients with a cCR.
- Trial name
- NCT03846726
- Testing
- standard TME surgery
- Where
- China
- Volunteers
- 513 people
- Sponsor
- Yuan-hong Gao
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma(MZL)
Watch and Wait or Worry and Wait in Indolent Lymphoma
Indolent lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, low-grade follicular lymphoma, and Waldenström macroglobulinemia, are slow-growing cancers often managed initially…
- Conditions
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma(MZL), Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2
- Trial name
- NCT07173790
- Testing
- Patient-Reported Outcomes Survey
- Where
- 4 sites in South Korea
- Volunteers
- 250 people
- Sponsor
- Seoul National University Hospital
Rectal Cancer
The Development of a Patient Reported Outcomes Measure Committed to the Watch-and-wait Program for Rectal Cancer
The purpose of this study to develop an international tool that can be used to assess burden of disease in patients enrolled in the W\&W program for rectal cancer
- Trial name
- NCT05040646
- Testing
- Delphi exercise
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Rectal Cancer, Neoadjuvant Therapy
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Background There is currently no reliable means to restage rectal cancers after neoadjuvant chemoradiation. There are still no reliable methods to identify patients with pCR before radical surgery.
- Conditions
- Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
- Trial name
- BIOPSY (NCT04743102)
- Testing
- multi-points and full-thickness Biopsy, traditional cCR
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Beijing Chao Yang Hospital
Rectal Neoplasms
Watch and Wait as Treatment for Patients With Rectal Cancer
A national cohort study with all patients scheduled for neoadjuvant treatment with (chemo)radiotherapy or short course radiotherapy with delayed surgery 6-8 weeks) for rectal cancer staged as cT4bNX/anycTanycN and…
- Trial name
- WoW (NCT03125343)
- Testing
- endoscopy, Surgery, MRI
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Esophageal Squamous Cell Carcinoma
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete…
- Trial name
- WATCHER (NCT05507411)
- Testing
- Neoadjuvant Radiotherapy, Neoadjuvant Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Neoplasms
Brazilian Total Neoadjuvant Therapy Trial
Standard therapy for localized rectal cancer includes chemotherapy and radiation therapy, followed by a "recovery" period of 7-12 weeks, surgery and adjuvant chemotherapy for 3-6 months.
- Trial name
- BRAZIL-TNT (NCT05081687)
- Testing
- Folfirinox
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Hospital Israelita Albert Einstein
Rectal Cancer
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
The goal of this clinical trial is to test the safety and efficacy of local excision (LE) or non-operative management (NOM) in patients with MRI defined low-risk rectal cancer following neoadjuvant intensity modulated…
- Trial name
- NCT06209099
- Testing
- Nonoperative Management (NOM), Local Excision (LE), Total Mesorectal Excision (TME)
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients
Total neoadjuvant treatment (TNT) including radiotherapy and induction or consolidation systemic chemotherapy has become the standard treatment for patients with stage II and III rectal adenocarcinoma.
- Trial name
- PREDIR-NEOREC (NCT06762405)
- Testing
- radiotherapy, Dostarlimab, Biological study on circulating tumor DNA (optional for the patient)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Rectal Cancer
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin/fluorouracil-based chemotherapy (CAPOX) for cT2 rectal…
- Trial name
- AMBITION (NCT05939661)
- Testing
- Radiation, Chemotherapy, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Osaka University
Clinical Complete Response Rate With Negative MRD
The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.
This study is a single arm, single center, phase II, prospective clinical study aimed at exploring the effectiveness and safety of watch and wait strategy guided by dynamic minimal disease residual (MRD) monitoring to achieve…
- Trial name
- WINDOW (NCT06477991)
- Testing
- Tireilizumab（PD-1 inhibitor）
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Yunnan Cancer Hospital
HCC - Hepatocellular Carcinoma, Watch & Wait
Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
The "Surgery versus Maintenance after Conversion-therapy-achieved Complete/Partial Response in Hepatocellular Carcinoma (SWITCH)" study is a multicenter, open-label, prospective non-randomized cohort study with the protocol…
- Conditions
- HCC - Hepatocellular Carcinoma, Watch & Wait, Surgery
- Trial name
- SWITCH (NCT07410715)
- Testing
- Surgical Resection, Maintenance Therapy Group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- West China Hospital
Rectal Cancer
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
Immunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) , more than fifty percent of dMMR/MSI-H CRC patients might get…
- Trial name
- BASKET (NCT04643041)
- Testing
- watch and wait
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Ovarian Cancer
Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer.
The purpose of this study in women who have completed primary treatment for ovarian cancer is to investigate the effects of individualised follow-up care delivered by a nurse compared to conventional medical follow-up on quality…
- Trial name
- NCT02298855
- Testing
- Individualised follow-up
- Where
- 3 sites in United Kingdom
- Volunteers
- 113 people
- Sponsor
- University College, London
Lymphoma
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00112931
- Testing
- rituximab, No treatment
- Where
- 72 sites in Australia, New Zealand and 1 more
- Volunteers
- 462 people
- Sponsor
- University College, London
Locally Advanced Rectal Adenocarcinoma
Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
The primary objective of the NACRE-2 trial is to assess whether the addition of chemotherapy after short-course radiotherapy is more effective than short-course radiotherapy alone in elderly patients with locally advanced rectal…
- Trial name
- NACRE-2 (NCT07118800)
- Testing
- FOLFOX4s, Short Course Radiotherapy
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Rectal Cancer
Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial
Open to patients undergoing any pre-operative treatment for locally advanced rectal cancer, TRIGGER is the only phase III clinical trial in the UK offering watch and wait.
- Trial name
- TRIGGER (NCT02704520)
- Testing
- High resolution MRI scan, mrTRG assessment
- Where
- 10 sites in United Kingdom
- Volunteers
- 441 people
- Sponsor
- Imperial College London
Rectal Neoplasms
Study for Wait and Watch Suitable in Rectal Cancer
One of the standard treatment options offered to patients of locally advanced rectal cancer is neoadjuvant (treatment given before surgery) radiotherapy \& chemotherapy followed by surgery.
- Trial name
- ARROW (NCT06252142)
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Centre